Registration | Contact Us | Site Map | Alerts | Archives | Subscribe to the Paper



its high cost. In addition, regulation and reimbursement issues have challenged the company: Because the Food and Drug Administration has not been willing to approve the most commonly used radioisotope for PET, Medicare and insurance companies aren't willing to reimburse hospitals for the procedure.

Douglass said one of the first goals of CTI was to make PET less expensive.

"When we first started doing PET at CTI, 2 to 21/2 million (dollars) of cyclotron and 2 to 21/2 million (dollars) of scanner is what you had to have to get into it ."

Ward Digby, vice president of marketing for CTI, said the cyclotrons needed to make the radiopharmaceuticals now cost

around \$1.3 million, and the scanners range from just under \$1 million to about \$2 million. A clinic or hospital putting in a new PET center would face a cost of about \$3 million, depending on how much site preparation is required.

Once installed, the equipment requires technicians and chemists -- and more money. Curtis Curley, the University of Tennessee Medical Center's vice chancellor of business and finance, estimated it will cost \$900,000 to run UT's PET center this year.

A PET scan of the brain costs about \$1,500 and a whole-body scan is \$2,000. In comparison, an MRI scan is \$1,240. The problem for patients comes with the bill. Most MRIs are automatically covered by insurance. The most commonly used tracer in PET is FDG, or flouro-deoxy-glucose, and after 20 years, the FDA has not yet approved its use because the agency is still not completely convinced of the tracer's safety.

What this means to the patient is that many insurance companies will refuse to reimburse the hospital for the cost of the PET scan.

This has been a thorn in the side of CTI.

"Our whole strategy, whole approach has been we just simply think PET should be reimbursed when it's demonstrated that it's clinically effective and cost-effective," Douglass said."It's hard to argue with that. There's so much regulatory uncertainty that only the large institutions were going to buy PET. But even when you consider all the problems they had to face, we still have 70 institutions in the U.S. that have PET and 150 worldwide."

* * *

Douglass admitted the company has a lot to lose in the U.S. if the Food and Drug Administration does not approve FDG. That's why he's been working with Sen. Bill Frist, R-Tenn., and Sen. Ted Stevens, R-Alaska, helping with their efforts to draft legislation to force the FDA to approve the radiopharmaceuticals used in PET and ease reimbursement. Lee Rawls, chief of staff in Frist's office, said progress of the section of Senate Bill S 830 called ``PET Compounding and Reimbursement Act of 1997'' has been good. The first hurdle, the ``mark-up'' phase of the bill, has been cleared with the PET section intact. The next stop is the Senate floor on July 21.

Meanwhile, an increasing number of private insurance companies are willing to pay. ``If it's not an emergency, patients can call their insurance company and many will be approved on a case-by-case basis," said CTI vice president Digby.

Douglass said the next push for the company is establishing sites where FDG will be manufactured and then distributed to area hospitals with scanners. Because of the rate at which FDG decays, the hospitals need to be within a 21/2-hour commute of their source of radiopharmaceuticals.

``A major part of our strategy is to be able to increase the number of our distribution centers," Douglass said. CTI has distribution centers in Phoenix; Los Angeles, Sacramento, Palo Alto or San Francisco, Calif.; Omaha, Neb.; Chicago; Peoria, Ill.; Nashville; Tampa, Fla.; New York; Atlanta; and Detroit.

Douglass said it is likely that a distribution center will be added at UT Medical Center.

Where does he see this trend going?

"I think there needs to be 100 distribution centers," he said. "If you look at where PET's application is, a million studies per year in the U.S. would not be an exceptional number of studies to be done. There are 14 million conventional nuclear medical studies done per year. To penetrate 7 or 10 percent of that market is not unreasonable for PET.

"To do that, though, requires about 100 distrbution centers, one in just about every significant metropolitan area in the United States. I see no reason, other than capital and personnel, why one would not be able to do that."

* * *

CTI Inc. is the parent company for four affiliates:

* CTI Cyclotron Systems -- production, marketing, sales and service of the cyclotrons, which are mini-particle accelerators where the radiopharmaceuticals are synthesized.

* CTI PET Systems Inc. -- scanner research and development, production, marketing, sales and service.

* CTI Services Inc. -- sources, infusion systems and PETNet FDG Distribution Systems.

* CTI Detector Systems -- detector (used in the scanners) research and development, production, marketing and sales.

Seventy-two percent of the shareholders in the parent company are officers and employees of CTI. Siemens holds 3 percent, Mitsui 10 percent and others 15 percent. The affiliated company CTI PET Systems Inc. is jointly held by Siemens, 49.9 percent, and CTI, 50.1 percent.

	Copyright 2005 - KnoxNews.com is an E.W. Scripps Company website.		User Agreement
P	Other E.W. Scripps sites:	B	Privacy Policy Subscriptions Media Kit
			Contact Us

Advertising Information: Contact Jennifer Corum or call (865) 342-6553.